ArticleLung2025
Differences in Blood Eosinophil Level During Stable Disease and During Exacerbation of COPD and Exacerbation Risks.
Article in Lung, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Biologics for eosinophilic COPD: current applications and future prospects.Frontiers in immunology · 2026Review
- The Role of Advanced Lung Cancer Inflammation Index in Predicting COPD Exacerbation Risks.International journal of chronic obstructive pulmonary disease · 2026Article
- Latent Class Analysis to Identify Novel Phenotypes in Exacerbations of COPD: A Retrospective, Multicenter Cohort Study.MedComm · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough blood eosinophil count (BEC) has been extensively studied as a biomarker in chronic obstructive pulmonary disease (COPD), there remain challenges and controversy in using a single reading. It has not been determined whether the difference in BEC between baseline and that during an acute exacerbation of COPD (AECOPD) has any role in predicting subsequent AECOPD.
methodsA prospective study was conducted to investigate the possible role of differences in BEC from baseline to that during AECOPD to predict future AECOPD risk. The BEC difference was expressed as absolute eosinophil difference: BEC at index moderate-to-severe exacerbation (E
resultsAmong 348 Chinese patients with COPD, 158 who experienced an index moderate-to-severe AECOPD were analyzed. Using the cut-off of 105 cells/µL for absolute eosinophil difference as determined by receiver operating characteristic (ROC) analysis, patients with absolute eosinophil difference ≥ 105 cells/µL had a shorter time to subsequent AECOPD with adjusted hazard ratio (aHR) of 1.68 (95% CI = 1.02-2.74; p = 0.040). They also had a higher annual number of subsequent AECOPD (2.49 ± 2.84/year vs 1.58 ± 2.44/year, p = 0.023). Similar findings were shown in the subgroup with stable-state baseline BEC < 300 cells/µL.
conclusionGreater difference in BEC between baseline and upon moderate-to-severe AECOPD might be associated with shorter time to next AECOPD, as well as more episodes of subsequent AECOPD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.